Clinical Trial

Application of Artificial Intelligence and Iron Metabolism Markers in Predicting ICU Outcomes for Critically Ill Cancer Patients

Completed
View on ClinicalTrials.gov →
Summary
This study aimed to develop a more accurate way to predict the 30-day survival of cancer patients admitted to the intensive care unit (ICU). The researchers focused on markers of iron metabolism, as imbalances in iron are common in cancer and severe illness. The study analyzed data from 1,137 critically ill cancer patients. Using artificial intelligence (AI), specifically a model called TabPFN, the study combined these iron markers with other routine clinical data (like blood cell counts and lactate levels) to create a new prediction tool.
Trial Details
NCT Number NCT07408661
Lead Sponsor Tongji University
Conditions Cancer
Enrollment 1,137 participants
Start Date 2015-01-01
Primary Completion 2024-10-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-13